Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Standards of Care II01:19

Standards of Care II

709
Nurses bear specific legal responsibilities under several federal statutes, including:
709
Cancer Prevention02:59

Cancer Prevention

6.3K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.3K
Standards of Care I01:22

Standards of Care I

748
Federal statutes profoundly impact nursing practice, providing critical guidelines to ensure patient care is equitable, accessible, and of the highest quality. The following laws address distinct aspects of healthcare provision and patient rights:
748

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology.

JCO precision oncology·2026
Same author

Extracellular vesicles in prostate cancer: current understanding and future perspectives.

Journal of the National Cancer Center·2026
Same author

NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial.

European urology·2026
Same author

Early treatment outcome prediction in metastatic castration-resistant prostate cancer utilizing 3-month tumor growth rate (<i>g</i>-rate) based machine learning model.

medRxiv : the preprint server for health sciences·2026
Same author

Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes Analysis.

JCO precision oncology·2026

Related Experiment Video

Updated: Aug 17, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

338

NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.

Edward M Schaeffer1, Sandy Srinivas2, Nabil Adra3

  • 11Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Journal of the National Comprehensive Cancer Network : JNCCN
|December 12, 2022
PubMed
Summary

The National Comprehensive Cancer Network (NCCN) updated prostate cancer guidelines, focusing on systemic therapy for metastatic disease. These revisions incorporate recent clinical data to refine treatment strategies for advanced prostate cancer patients.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K

Related Experiment Videos

Last Updated: Aug 17, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

338
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K

Area of Science:

  • Oncology
  • Urology
  • Clinical Practice Guidelines

Background:

  • The NCCN Guidelines for Prostate Cancer provide comprehensive recommendations for diagnosis, staging, risk assessment, and management of prostate cancer.
  • These guidelines cover localized, regional, recurrent, and metastatic disease stages.
  • The NCCN Prostate Cancer Panel convenes annually to ensure recommendations reflect the latest clinical evidence.

Purpose of the Study:

  • To summarize key updates from the 4.2022 and 1.2023 NCCN Guidelines for Prostate Cancer.
  • To highlight revisions concerning systemic therapy for metastatic prostate cancer.
  • To inform clinicians about the most current evidence-based treatment options.

Main Methods:

  • Review of NCCN Prostate Cancer Panel meeting discussions and updated guideline content.
  • Analysis of new clinical data influencing recommendations for metastatic prostate cancer.
  • Synthesis of panel insights regarding systemic therapy advancements.

Main Results:

  • The 4.2022 and 1.2023 guideline updates include specific revisions to systemic therapy recommendations for metastatic prostate cancer.
  • These updates reflect the panel's evaluation of new clinical data and expert input.
  • The focus is on refining management strategies for advanced disease.

Conclusions:

  • The NCCN Guidelines for Prostate Cancer are dynamically updated to incorporate the latest research and clinical findings.
  • Recent updates provide crucial information on systemic therapy for metastatic prostate cancer.
  • Adherence to these updated guidelines supports optimal patient care and outcomes.